CD4 and neoplasm: The TLR7 antagonist Loxoribin inhibited tumor growth in xenograft models of colon cancer and lung cancer by promoting CD4+ T cell proliferation, reversing CD4+CD25+ Treg-mediated suppression via DCs [13, 147].